08 Apr 2008
A diagnostic test designed to give early diagnosis of neurodegenerative diseases including Alzheimer's and Parkinson's disease could be launched in Europe by this summer.
The test, NuroPro, could initially be launched in Greece before expansion to the US in the autumn, SCI Chemistry & Industry magazine reports.
Manufactured by Power3 Medical Products, the test has identified and patented blood proteins associated with neurodegenerative diseases.
Some 59 protein biomarkers can be measured by the test to distinguish between Alzheimer's, Parkinson's and Lou Gehrig's disease.
Specificity and sensitivity for the test rates is in the high 90s, Power3 claims, with two clinical validation studies currently underway in Greece and the US.
"There is currently no diagnostic test for any neurodegenerative disease on the market - diagnoses are currently based solely on a clinical diagnosis of symptoms," Power3 chief executive, Steve Rash explained.
Kieran Breen, director of research at the Parkinson's Disease Society, said the test could aid in monitoring the progression of disease and assessing the effectiveness of drugs.
However he gave a cautious welcome to the announcement, saying more research had to be undertaken.
"While the test seems promising, larger studies need to be conducted before it can be confirmed as being helpful in making a diagnosis," he said.
Click here for EPG Online Physician's tools including disease awareness, diagnosis tools, treatment options and management guidance
Print Article 
Bookmark
Disease Knowledge Centres feed
-
TRITACE Tablets - 24.72%
... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ... -
TRITACE Titration Pack - 24.36%
... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ... -
BETAFERON - 23.54%
... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ... -
LOCOID Ointment - 22.5%
The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ... -
NAGLAZYME Solution for Infusion - 22.5%
... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ... -
ELAPRASE Solution for Infusion - 22.5%
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...
Printed on 08/01/2009 8:49 PM
